Moneycontrol
Get App
you are here: HomeNewsBusiness
Last Updated : Sep 10, 2019 10:31 AM IST | Source: PTI

Glenmark gets USFDA nod for plaque psoriasis treatment drug

"Glenmark Pharmaceuticals, USA, has been granted final approval by the United States Food and Drug Administration (USFDA) for Clobetasol Propionate Foam, 0.05 percent (emulsion formulation)," Glenmark said in a regulatory filing.

Representative image
Representative image
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Drug major Glenmark Pharma on Tuesday said it has received final approval from the US health regulator for Clobetasol Propionate Foam, indicated for treatment of plaque psoriasis. The approved product is a generic version of Olux-E Foam, 0.05 percent, of Mylan Pharmaceuticals.

"Glenmark Pharmaceuticals, USA, has been granted final approval by the United States Food and Drug Administration (USFDA) for Clobetasol Propionate Foam, 0.05 percent (emulsion formulation)," Glenmark said in a regulatory filing.

Quoting to IQVIA sales data for the 12 month period ending July 2019, Glenmark said the Olux-E Foam, 0.05 percent, market achieved annual sales of approximately USD 11.1 million.

Close
Glenmark said current portfolio consists of 161 products authorised for distribution in the US marketplace and 54 abbreviated new drug applications are pending approval with the USFDA.

Get access to India's fastest growing financial subscriptions service Moneycontrol Pro for as little as Rs 599 for first year. Use the code "GETPRO". Moneycontrol Pro offers you all the information you need for wealth creation including actionable investment ideas, independent research and insights & analysis For more information, check out the Moneycontrol website or mobile app.
First Published on Sep 10, 2019 10:28 am
Loading...
Sections
Follow us on
Available On
PCI DSS Compliant